Pharmacognosy Institute and Department of Pharmaceutical Sciences, University of Illinois Chicago College of Pharmacy, 833 S. Wood Street, Chicago, Illinois 60612, United States.
J Nat Prod. 2024 Nov 22;87(11):2665-2675. doi: 10.1021/acs.jnatprod.4c00439. Epub 2024 Oct 29.
Natural products (NPs) continue to inform the discovery and development of a diversity of drugs, both marketed and investigational. Pain, one of the most common of human experiences and profound challenges in medicine and biology, has emerged at the core of an urgent societal problem, in the United States and globally. The present study employs a retrospective analysis of an extensive set of published literature curated in the NAPRALERT database to identify NPs with experimental evidence of bioactivity supporting the selection and prioritization of NP leads with promise in pain management. The NAPRALERT pain data set currently documents >38,000 pain-relevant experiments reported in >1,750 distinct journals. The evidence presented here was annotated from >10,000 distinct scientific publications identifying NP extracts and isolates with experimental biological data indicating positive mitigation of pain, inflammation, and/or modulation of nociceptive signaling targets. Correlation of ethnomedical uses with experimental data represents a value-added approach to the selection and prioritization of leads. Dissemination of this unique NP/pain data set, with experimental data and information applicable to basic, translational, and clinical science stakeholders alike, furnishes practical evidence in support of a rational selection of NPs for directed pain research. A large portion of the NAPRALERT pain-relevant data set, along with a set of query tools designed to assist user-directed selection and prioritization of leads, are presented as Supporting Information in order to mitigate the limitations inherent in presenting such a large data set in (print) format. To support user efforts, this report involves explication of NAPRALERT data organization and the articulation of rational approaches to user-guided selection of evidence-based NP leads.
天然产物(NPs)继续为各种药物的发现和开发提供信息,包括已上市和正在研究的药物。疼痛是人类最常见的体验之一,也是医学和生物学面临的巨大挑战,它已成为美国乃至全球一个紧迫的社会问题的核心。本研究采用回顾性分析方法,对 NAPRALERT 数据库中广泛收集的已发表文献进行分析,以确定具有支持选择和优先考虑具有疼痛管理潜力的 NP 先导物的实验证据的 NP。NAPRALERT 疼痛数据集目前记录了 >38000 项与疼痛相关的实验,这些实验分别在>1750 种不同的期刊中报道。这里呈现的证据是从>10000 种不同的科学出版物中注释出来的,这些出版物确定了具有实验生物学数据的 NP 提取物和分离物,这些数据表明它们可以积极缓解疼痛、炎症和/或调节伤害性信号靶标。将民族医学用途与实验数据相关联是选择和优先考虑先导物的一种增值方法。传播这种独特的 NP/疼痛数据集,以及适用于基础、转化和临床科学利益相关者的实验数据和信息,为有针对性地选择 NP 进行疼痛研究提供了实用证据。NAPRALERT 疼痛相关数据集的很大一部分,以及一组旨在协助用户导向的先导物选择和优先化的查询工具,都作为支持信息呈现,以减轻在(印刷)格式中呈现如此大数据集所固有的限制。为了支持用户的努力,本报告涉及 NAPRALERT 数据组织的说明以及用户引导的基于证据的 NP 先导物选择的合理方法的阐述。